IN THE CLAIMS:

Please cancel claims 1, 2, 3, 4 and 9, without prejudice.

Please amend claims 22, 23 and 72 to read as follows:

- 22. (Amended) Ondansetron hydrochloride Form B characterized by powder X-ray diffraction peaks at 10.5, 11.9, 13.0, 13.5, 15.1, 20.9, 22.7, 24.0, and 25.7 ± 0.2 degrees two-theta.
- 23. (Amended) A pharmaceutical composition comprising the ondansetron hydrochloride of any of claims 19 through 22 and a pharmaceutically acceptable carrier.
- 72. (Amended) Ondansetron hydrochloride methanolate.

A2